Belantamab mafodotin vs CBG002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Belantamab mafodotin
Marketed by GlaxoSmithKline
NCT04246047 · Phase 3 · active, not recruiting
Patients were randomized (243 vs 251) against an active comparator and the primary endpoint of progression-free survival, assessed by an independent review committee, was met with a large separation (hazard ratio 0.41, p<0.00001). The study was open-label with no masking of participants or investigators, which keeps it below the highest grade.
Next expected readout: February 2027 · NCT05055063 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) (Up to approximately 41 months): Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5) (met)
Result source: NCT04246047
CBG002
Developed by Zhejiang Carbiogene Therapeutics Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT06705725 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Belantamab mafodotin
- 36.6 vs 13.4vs DaratumumabNCT04246047
13 other results
- 11.2 vs 7 NCT04162210
- 3.2 NCT03525678
- 3.9 NCT03525678
- 2.2 NCT03525678
- 2.8 NCT03525678
- 3.6 NCT03525678
- 5.7 NCT03525678
- 5.7 NCT05064358
- 2.8 NCT05064358
- 2.5 NCT03848845
- 2.1 NCT05064358
- 2.7 NCT05064358
- 2.8 NCT05064358
- CBG002
- —Not reported
OS, median
- Belantamab mafodotin
- 24 vs 22.9vs Pomalidomide Plus DexamethasoneNCT04162210
7 other results
- 14 NCT03525678
- 15.3 NCT03525678
- 24.5 NCT03525678
- 20.9 NCT05064358
- 13.5 NCT05064358
- 15 NCT05064358
- 14.5 NCT05064358
- CBG002
- —Not reported
ORR
- Belantamab mafodotin
- 41% vs 36%vs Pomalidomide Plus DexamethasoneNCT04162210
35 other results
- 34% NCT03525678
- 30% NCT03525678
- 31% NCT03525678
- 48% NCT03525678
- 30% NCT03525678
- 50% NCT03544281
- 69% NCT03544281
- 69% NCT03544281
- 69% NCT03544281
- 92% NCT03544281
- 75% NCT03544281
- 62% NCT03544281
- 78% NCT03544281
- 43% NCT03848845
- 58% NCT03544281
- 50% NCT03544281
- 83% NCT03544281
- 75% NCT03544281
- 32% NCT03525678
- 33% NCT03525678
- 52% NCT03525678
- 26% NCT03525678
- 33% NCT03525678
- 33% NCT05064358
- 28% NCT05064358
- 25% NCT05064358
- 25% NCT05064358
- 43% NCT03848845
- 67% NCT03848845
- 18% NCT05064358
- 25% NCT03828292
- 50% NCT03828292
- 100% NCT03828292
- 50% NCT03828292
- 16.7% NCT04177823
- CBG002
- —Not reported
VGPR or better
- Belantamab mafodotin
- 25%bNCT05064358
4 other results
- 8% NCT05064358
- 18% NCT05064358
- 15% NCT05064358
- 18% NCT05064358
- CBG002
- —Not reported
MRD negativity
- Belantamab mafodotin
- —Trial running · NCT06679101
- CBG002
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
CBG002: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Belantamab mafodotin: 3 of 4 rows · CBG002: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Belantamab mafodotin |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3 show 56 more results42.2% NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 n/a: no completion milestone3.4 mg/kg NCT03525678 · Phase 2 n/a: no completion milestone3.4 mg/kg NCT03525678 · Phase 2 —3.4 mg/kg NCT03525678 · Phase 2 n/a: no completion milestone2.5 mg/kg NCT03525678 · Phase 2 —2.5 mg/kg NCT03525678 · Phase 2 75%2.5 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 80%2.5 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 82.5%1.9 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 77.5%1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 58.8%1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence · combination 50%3.4 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 77.8%2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 69.2%2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 69.2%2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 87.5%2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 69.2%2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 75%1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 66.7%1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 42.9%3.4 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 32.1%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 25%3.4 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence 0%2.5 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence —2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 33.3% NCT04177823 · Phase 1 · registry result, not featured evidence 16.7%4.60 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 33.3%3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 25%2.50 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%1.92 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.96 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.48 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.24 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.12 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.06 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.03 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3 show 56 more results— NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 —3.4 mg/kg NCT03525678 · Phase 2 —3.4 mg/kg NCT03525678 · Phase 2 —3.4 mg/kg NCT03525678 · Phase 2 —2.5 mg/kg NCT03525678 · Phase 2 —2.5 mg/kg NCT03525678 · Phase 2 —2.5 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence —2.5 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence —1.9 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence —1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence —1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence · combination —3.4 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination —3.4 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence —2.5 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence —2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination —2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination — NCT04177823 · Phase 1 · registry result, not featured evidence —4.60 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —2.50 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —1.92 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.96 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.48 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.24 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.12 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.06 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence —0.03 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 50%a NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3 show 56 more results46.5% NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 53.5%3.4 mg/kg NCT03525678 · Phase 2 62.5%3.4 mg/kg NCT03525678 · Phase 2 100%3.4 mg/kg NCT03525678 · Phase 2 45.3%2.5 mg/kg NCT03525678 · Phase 2 100%2.5 mg/kg NCT03525678 · Phase 2 43.6%2.5 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 53.8%2.5 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 42.5%1.9 mg/kg Q3W NCT05064358 · Phase 2 · registry result, not featured evidence 40%1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence 23.5%1.9 mg/kg Q6W NCT05064358 · Phase 2 · registry result, not featured evidence · combination 56.3%3.4 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%3.4 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 72.2%2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 53.8%2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 62.5%2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 46.2%2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%2.5 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%2.5 mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 25%2.5 mg/kg Step-Down STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%2.5mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%2.5mg/kg SPLIT NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 66.7%1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 66.7%1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 25%1.9 mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 50%1.9 mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 0%1.9mg/kg SINGLE NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 33.3%1.9mg/kg STRETCH NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 71.4%3.4 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 66.7%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 17.9%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 0%2.5 mg/kg + 200 mg NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 0%3.4 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence 50%2.5 mg/kg NCT03828292 · Phase 1 · registry result, not featured evidence 0%2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 25%2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 50%2.5 mg/kg + Bor/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 0%2.5 mg/kg + Pom/Dex NCT03828292 · Phase 1 · registry result, not featured evidence · combination 16.7% NCT04177823 · Phase 1 · registry result, not featured evidence 50%4.60 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 33.3%3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 48.6%3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 50%3.40 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 50%2.50 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 50%1.92 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.96 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 25%0.48 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 25%0.24 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 25%0.12 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.06 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence 0%0.03 mg/kg NCT02064387 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a thrombocytopenia 69% vision blurred 66.1% dry eye 50.8% NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3 show 56 more resultsvision blurred 48.4% dry eye 37.8% foreign body sensation in eyes 36.9% NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 2.5 mg/kg Q3W vision blurred 41% dry eye 38.5% eye irritation 28.2% NCT05064358 · Phase 2 · registry result, not featured evidence 2.5 mg/kg Q6W vision blurred 46.2% thrombocytopenia 33.3% anaemia 30.8% NCT05064358 · Phase 2 · registry result, not featured evidence 1.9 mg/kg Q3W thrombocytopenia 42.5% anaemia 30% dry eye 30% NCT05064358 · Phase 2 · registry result, not featured evidence 1.9 mg/kg Q6W anaemia 37.5% dry eye 30% eye irritation 27.5% NCT05064358 · Phase 2 · registry result, not featured evidence 1.9 mg/kg Q6W vision blurred 52.9% dry eye 47.1% eye irritation 29.4% NCT05064358 · Phase 2 · registry result, not featured evidence · combination 3.4 mg/kg SINGLE keratopathy 93.8% thrombocytopenia 56.3% neuropathy peripheral 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 3.4 mg/kg SPLIT keratopathy 83.3% thrombocytopenia 75% fatigue 41.7% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 3.4 mg/kg SPLIT abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg SINGLE keratopathy 83.3% vision blurred 66.7% platelet count decreased 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg SPLIT keratopathy 76.9% thrombocytopenia 69.2% vision blurred 38.5% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg STRETCH keratopathy 100% platelet count decreased 58.3% gamma-glutamyltransferase increased 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg Step-Down STRETCH keratopathy 100% platelet count decreased 58.3% diarrhoea 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5mg/kg SINGLE keratopathy 68.8% fatigue 43.8% thrombocytopenia 43.8% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5mg/kg SPLIT keratopathy 92.3% vision blurred 53.8% diarrhoea 46.2% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg SINGLE abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg SPLIT abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg Step-Down STRETCH abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5mg/kg SINGLE abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 2.5mg/kg SPLIT abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9 mg/kg SINGLE keratopathy 91.7% platelet count decreased 75% constipation 66.7% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9 mg/kg STRETCH keratopathy 75% diarrhoea 50% platelet count decreased 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9mg/kg SINGLE diarrhoea 75% keratopathy 75% abdominal pain 50% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9mg/kg STRETCH keratopathy 75% diarrhoea 41.7% insomnia 41.7% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9 mg/kg SINGLE abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9 mg/kg STRETCH abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9mg/kg SINGLE abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 1.9mg/kg STRETCH abdominal discomfort 0% abdominal distension 0% abdominal pain 0% NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination 3.4 mg/kg + 200 mg keratopathy 85.7% pyrexia 57.1% anaemia 42.9% NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg + 200 mg keratopathy 100% anaemia 66.7% blepharitis 50% NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg + 200 mg keratopathy 71.4% pyrexia 35.7% vision blurred 35.7% NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 2.5 mg/kg + 200 mg alanine aminotransferase increased 0% anaemia 0% arthralgia 0% NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination 3.4 mg/kg diarrhoea 50% enterocolitis 50% headache 50% NCT03828292 · Phase 1 · registry result, not featured evidence 2.5 mg/kg platelet count decreased 100% alanine aminotransferase increased 50% aspartate aminotransferase increased 50% NCT03828292 · Phase 1 · registry result, not featured evidence 2.5 mg/kg + Bor/Dex thrombocytopenia 100% diarrhoea 66.7% insomnia 66.7% NCT03828292 · Phase 1 · registry result, not featured evidence · combination 2.5 mg/kg + Pom/Dex constipation 50% neutrophil count decreased 50% oedema peripheral 50% NCT03828292 · Phase 1 · registry result, not featured evidence · combination 2.5 mg/kg + Bor/Dex abdominal pain upper 0% abnormal faeces 0% alanine aminotransferase increased 0% NCT03828292 · Phase 1 · registry result, not featured evidence · combination 2.5 mg/kg + Pom/Dex abdominal pain upper 0% abnormal faeces 0% alanine aminotransferase increased 0% NCT03828292 · Phase 1 · registry result, not featured evidence · combination blood lactate dehydrogenase increased 66.7% hyponatraemia 66.7% lymphocyte count decreased 66.7% NCT04177823 · Phase 1 · registry result, not featured evidence 4.60 mg/kg thrombocytopenia 83.3% aspartate aminotransferase increased 66.7% fatigue 66.7% NCT02064387 · Phase 1 · registry result, not featured evidence 3.40 mg/kg vision blurred 100% aspartate aminotransferase increased 66.7% chills 66.7% NCT02064387 · Phase 1 · registry result, not featured evidence 3.40 mg/kg vision blurred 51.4% cough 40% aspartate aminotransferase increased 37.1% NCT02064387 · Phase 1 · registry result, not featured evidence 3.40 mg/kg vision blurred 33.3% anaemia 16.7% blood creatine phosphokinase increased 16.7% NCT02064387 · Phase 1 · registry result, not featured evidence 2.50 mg/kg anaemia 37.5% fatigue 37.5% nausea 37.5% NCT02064387 · Phase 1 · registry result, not featured evidence 1.92 mg/kg nausea 75% vision blurred 75% chills 50% NCT02064387 · Phase 1 · registry result, not featured evidence 0.96 mg/kg anaemia 66.7% fatigue 66.7% chills 33.3% NCT02064387 · Phase 1 · registry result, not featured evidence 0.48 mg/kg arthralgia 50% back pain 25% decreased appetite 25% NCT02064387 · Phase 1 · registry result, not featured evidence 0.24 mg/kg fatigue 50% nausea 50% anaemia 25% NCT02064387 · Phase 1 · registry result, not featured evidence 0.12 mg/kg cough 50% hypercalcaemia 50% nausea 50% NCT02064387 · Phase 1 · registry result, not featured evidence 0.06 mg/kg anaemia 100% diarrhoea 100% hyperuricaemia 100% NCT02064387 · Phase 1 · registry result, not featured evidence 0.03 mg/kg fatigue 100% neutropenia 100% osteonecrosis of jaw 100% NCT02064387 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 55 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Belantamab mafodotin
show 1 more result
show 34 more results
show 14 more results
show 15 more results
show 15 more results
+ 311 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Belantamab mafodotin's landscape · CBG002's landscape